@ 健康 时报 May 27th news, a study in the May 22nd of The Lancet reported that in the treatment of patients with new crowns, whether they use chloroquine or hydroxychloroquine alone or with macrolide Antibiotic use together, the patient’s mortality rate may be higher.
WHO Director General Tan Desai said at a regular press conference on May 15 that the WHO project team has suspended the trial of the hydroxychloroquine branch, But the trials of other branches are continuing.
Ji Lianmei, the founder of “Ask the Pharmacist” and the former pharmacist outpatient clinic of Beijing United Family Hospital, said: “The research of The Lancet is more about us A hint that the use of these drugs may increase the risk of mortality, and at the same time, no benefits are seen. In such cases, WHO stopped the trial of the drug and further statistical analysis of its safety data And evaluation. “
Ji Lianmei explained to the Health Times reporter that among the many studies of hydroxychloroquine in the world, some results are positive and some results are negative because of the The sample sizes vary, and the endpoints of the study design are different, making it difficult to draw a unified conclusion. The large-scale retrospective registration study published in The Lancet shows that after the patient sample size is large enough, it is found that the risk of using hydroxychloroquine to treat new coronary pneumonia is relatively high, especially because it may increase mortality. This is a The hardest outcome indicator in clinical research recognized by the medical community. Any large-scale research with such outcome indicators will consider suspending clinical trials to further evaluate and review the safety data of the drug that has been collected.
(Originally entitled “Why is WHO Stopping Hydroxychloroquine Drug Trials? Expert Interpretation”)